Johnson & Johnson (JNJCL) Stock Overview
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for JNJCL from our risk checks.
JNJCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$148,000.00 |
| 52 Week High | US$159,100.00 |
| 52 Week Low | US$138,900.00 |
| Beta | 0.40 |
| 1 Month Change | -3.90% |
| 3 Month Change | -3.90% |
| 1 Year Change | -5.09% |
| 3 Year Change | -6.32% |
| 5 Year Change | n/a |
| Change since IPO | 18.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNJCL | CL Pharmaceuticals | CL Market | |
|---|---|---|---|
| 7D | -3.9% | 0% | 0% |
| 1Y | -5.1% | 0% | 0% |
Return vs Industry: JNJCL underperformed the CL Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: JNJCL underperformed the CL Market which returned 20.3% over the past year.
Price Volatility
| JNJCL volatility | |
|---|---|
| JNJCL Average Weekly Movement | 1.3% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: JNJCL has not had significant price volatility in the past 3 months compared to the CL market.
Volatility Over Time: JNJCL's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 138,100 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Johnson & Johnson Fundamentals Summary
| JNJCL fundamental statistics | |
|---|---|
| Market cap | CL$361.37t |
| Earnings (TTM) | CL$20.88t |
| Revenue (TTM) | CL$85.51t |
Is JNJCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNJCL income statement (TTM) | |
|---|---|
| Revenue | US$89.33b |
| Cost of Revenue | US$27.78b |
| Gross Profit | US$61.55b |
| Other Expenses | US$39.74b |
| Earnings | US$21.81b |
Last Reported Earnings
Mar 30, 2025
Next Earnings Date
Jul 16, 2025
| Earnings per share (EPS) | 9.06 |
| Gross Margin | 68.90% |
| Net Profit Margin | 24.41% |
| Debt/Equity Ratio | 66.9% |
How did JNJCL perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 04:27 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/30 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Johnson & Johnson is covered by 59 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Charles Butler | Barclays |